The TSX Venture Exchange has accepted for filing a share exchange agreement dated Dec. 11, 2023, between the company, an arm's-length party and the target's shareholders, pursuant to which the company will acquire all of the issued and outstanding common shares of the target. The target has formulated sublingual strips to help maintain immune function and support metabolism.

Pursuant to the terms of the agreement, the company will issue 16,719,100 of the company's shares pro rata to the shareholders at a deemed price of five cents per share.

For further details, please refer to the company's news releases dated Dec. 11, 2023, and Jan. 18, 2024.